Literature DB >> 16023973

Steatosis and chronic hepatitis C virus infection: mechanisms and significance.

Keyur Patel1, Amany Zekry, John G McHutchison.   

Abstract

Chronic hepatitis C (CHC) and steatosis are common entities that have the potential to interact synergistically and result in significant morbidity. Steatosis is frequently observed in CHC and seems to have a significant impact on the natural history of the disease with respect to development of fibrosis and reducing the virologic response to current therapy. Research efforts should continue to focus on delineating the complex viral and host interactions involved in the pathogenesis of hepatitis C virus (HCV)-related steatosis. This may provide novel future therapeutic strategies that may help modulate disease progression in relation to steatosis in HCV infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023973     DOI: 10.1016/j.cld.2005.05.007

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  8 in total

1.  Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.

Authors:  Ke-Qin Hu; Sue L Currie; Hui Shen; Ramsey C Cheung; Samuel B Ho; Edmund J Bini; John D McCracken; Tim Morgan; Norbert Bräu; Warren N Schmidt; Lennox Jeffers; Teresa L Wright
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

2.  Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP).

Authors:  Silvia Mirandola; David Bowman; Mahmood M Hussain; Alfredo Alberti
Journal:  Nutr Metab (Lond)       Date:  2010-02-23       Impact factor: 4.169

Review 3.  Using high-throughput genomics to study hepatitis C: what determines the outcome of infection?

Authors:  Kathie-Anne Walters; Michael G Katze
Journal:  Antiviral Res       Date:  2009-01-07       Impact factor: 5.970

4.  Domain 3 of hepatitis C virus core protein is sufficient for intracellular lipid accumulation.

Authors:  Ravi Jhaveri; Guan Qiang; Anna Mae Diehl
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

5.  Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response.

Authors:  Kathie-Anne Walters; Michael A Joyce; Jill C Thompson; Maria W Smith; Matthew M Yeh; Sean Proll; Lin-Fu Zhu; T J Gao; Norman M Kneteman; D Lorne Tyrrell; Michael G Katze
Journal:  PLoS Pathog       Date:  2006-06-23       Impact factor: 6.823

Review 6.  Exploring the role of mast cells in the progression of liver disease.

Authors:  Shizhuan Huang; Haotian Wu; Feng Luo; Bin Zhang; Tianwei Li; Zongrui Yang; Bixuan Ren; Wenze Yin; Dehai Wu; Sheng Tai
Journal:  Front Physiol       Date:  2022-09-13       Impact factor: 4.755

7.  Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures.

Authors:  Martina Buck
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

8.  Treatment of non-alcoholic fatty liver disease.

Authors:  Keith G Tolman; Anthony S Dalpiaz
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.